Teleflex (NYSE:TFX) – Equities researchers at Leerink Swann issued their FY2021 earnings estimates for shares of Teleflex in a research note issued on Monday, May 14th. Leerink Swann analyst R. Newitter expects that the medical technology company will post earnings of $14.50 per share for the year. Leerink Swann has a “Outperform” rating and a $300.00 price objective on the stock.

Several other equities research analysts also recently weighed in on TFX. Stephens reaffirmed a “buy” rating and set a $300.00 price target on shares of Teleflex in a report on Thursday, January 18th. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. TheStreet downgraded Teleflex from an “a-” rating to a “c+” rating in a report on Monday, March 12th. Goldman Sachs started coverage on Teleflex in a report on Wednesday, April 4th. They set a “neutral” rating and a $257.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $293.00 price target (up from $285.00) on shares of Teleflex in a report on Thursday, May 3rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company’s stock. Teleflex currently has a consensus rating of “Hold” and an average target price of $280.80.

Shares of Teleflex opened at $259.10 on Tuesday, according to Marketbeat.com. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.18 and a quick ratio of 1.45. Teleflex has a 1-year low of $257.00 and a 1-year high of $260.37. The firm has a market cap of $12.08 billion, a P/E ratio of 30.85, a P/E/G ratio of 1.93 and a beta of 1.19.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, May 3rd. The medical technology company reported $2.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.94 by $0.21. Teleflex had a return on equity of 16.60% and a net margin of 7.51%. The firm had revenue of $587.23 million during the quarter, compared to the consensus estimate of $568.29 million. During the same period last year, the company earned $1.80 earnings per share. The company’s revenue for the quarter was up 20.4% on a year-over-year basis.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 15th. Shareholders of record on Tuesday, May 15th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date is Monday, May 14th. Teleflex’s dividend payout ratio (DPR) is currently 16.19%.

In other Teleflex news, Director Benson Smith sold 9,331 shares of the firm’s stock in a transaction on Monday, May 7th. The stock was sold at an average price of $272.98, for a total value of $2,547,176.38. Following the completion of the sale, the director now owns 77,498 shares of the company’s stock, valued at $21,155,404.04. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director George Babich, Jr. sold 2,500 shares of the firm’s stock in a transaction on Monday, April 23rd. The shares were sold at an average price of $270.66, for a total value of $676,650.00. Following the completion of the sale, the director now directly owns 9,358 shares of the company’s stock, valued at approximately $2,532,836.28. The disclosure for this sale can be found here. In the last three months, insiders sold 41,852 shares of company stock valued at $10,912,697. 2.56% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in TFX. Redmile Group LLC increased its position in shares of Teleflex by 449.9% in the fourth quarter. Redmile Group LLC now owns 172,486 shares of the medical technology company’s stock valued at $42,918,000 after buying an additional 141,121 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in shares of Teleflex by 14.0% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 16,543 shares of the medical technology company’s stock valued at $4,116,000 after buying an additional 2,035 shares in the last quarter. US Bancorp DE increased its position in shares of Teleflex by 8.4% in the fourth quarter. US Bancorp DE now owns 16,901 shares of the medical technology company’s stock valued at $4,205,000 after buying an additional 1,311 shares in the last quarter. Lombard Odier Asset Management Switzerland SA increased its position in shares of Teleflex by 14.7% in the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 6,343 shares of the medical technology company’s stock valued at $1,578,000 after buying an additional 815 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its position in shares of Teleflex by 72.3% in the fourth quarter. Glenmede Trust Co. NA now owns 3,102 shares of the medical technology company’s stock valued at $771,000 after buying an additional 1,302 shares in the last quarter. 88.96% of the stock is owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.